
Opinion|Videos|May 29, 2024
Overcoming Barriers to Better Patient Outcomes in PAH
Author(s)Ronald Oudiz, MD, FACP, FACC, FCCP
Ronald Oudiz, MD, FACP, FACC, FCCP, discusses the challenges and limitations associated with the adoption of new treatments and the impact of emerging therapies on patient outcomes, quality of life, and disease management in the long term.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What are the potential challenges or limitations associated with the adoption of new treatments, such as cost, access, or safety concerns?
- How might the evolving treatment landscape for PAH impact patient outcomes, quality of life, and disease management in the long term?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
2
FDA Approves Ziftomenib for R/R NPM1-Mutated AML
3
Government Shutdown Concluded but ACA Subsidies in Limbo
4
Managed Care Reflections: A Q&A With Laurie C. Zephyrin, MD, MPH, MBA
5















































